AI Medical Compendium Journal:
HIV clinical trials

Showing 1 to 1 of 1 articles

Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects.

HIV clinical trials Dec 1, 2018
BACKGROUND: Dolutegravir (DTG) plus boosted darunavir (bDRV) is a compact, adherence-friendly salvage regimen with the highest genetic barrier to HIV-1 resistance.
Humans Female Reproducibility of Results Aged Adult Male Middle Aged HIV Infections Cohort Studies Pyridones Oxazines Heterocyclic Compounds, 3-Ring Piperazines Italy HIV-1 Darunavir HIV Protease Inhibitors HIV Integrase Inhibitors Salvage Therapy
View on PubMed DOI
Popular Topics
Popular Journals